retatrutide glp-1 gip glucagon triple agonist Why is different 👇 Unlike older weight-loss injections, Retatrutide activates + + receptors, addressing: • Appetite regulation • Insulin resistance • Fat metabolism Not magic. Not cosmetic. Medical The Road towards Triple Agonists:

How These Results Compare to Other Weight Loss Medicines Retatrutide's 24.2% mean weight loss at 48 weeks exceeds phase 3 data for semaglutide 2.4 mg (~14.9% at 68 weeks) and is comparable to tirzepatide 15 mg (~22.5% at 72 weeks), though no direct head-to-head trials have been conducted

As the field advances, humanized preclinical systems that allow drug evaluation against human targetssuch as GCGR/GIPR/GLP1R humanized mouse modelswill play a pivotal role in bridging the gap between mechanistic discovery and clinical translation

For comparison of two groups, unpaired two-tailed Students t -tests were used

Over 75% of drug overdose deaths in 2022 involved opioids

They can if enrolled in a standalone Part D prescription drug plan, Medicare Advantage plan or any other plan that includes Part D drug coverage

32 Similarly, a study carried out in the United Kingdom showed a discontinuation rate of 45% and 65% at 12 and 24 months, respectively